Groupon vs Tango Therapeutics Which Is a Smarter Choice?

Groupon and Tango Therapeutics are two companies operating in vastly different sectors of the market. Groupon is a popular e-commerce platform offering deals and discounts on a wide range of products and services, while Tango Therapeutics is a biotechnology company focused on developing targeted cancer therapies. Stock performance for both companies has been subject to market conditions and company-specific factors. Investors looking to diversify their portfolio may consider comparing the two stocks to make informed investment decisions.

Groupon or Tango Therapeutics?

When comparing Groupon and Tango Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Groupon and Tango Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Groupon has a dividend yield of -%, while Tango Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Groupon reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Tango Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Groupon P/E ratio at 24.37 and Tango Therapeutics's P/E ratio at -2.51. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Groupon P/B ratio is 11.78 while Tango Therapeutics's P/B ratio is 1.35.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Groupon has seen a 5-year revenue growth of -0.82%, while Tango Therapeutics's is -0.86%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Groupon's ROE at 95.71% and Tango Therapeutics's ROE at -49.64%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $11.83 for Groupon and $2.80 for Tango Therapeutics. Over the past year, Groupon's prices ranged from $7.75 to $19.56, with a yearly change of 152.39%. Tango Therapeutics's prices fluctuated between $2.70 and $13.01, with a yearly change of 381.67%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.